Liquidia starts commercial shipment of FDA-approved YUTREPIA

MORRISVILLE, N.C. - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company valued at $1.28 billion, has begun its first commercial shipment of YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). This development comes swiftly after the U.S. Food and Drug Administration approved YUTREPIA on May 23, 2025, and is now available through specialty pharmacies. According to InvestingPro data, analysts anticipate significant sales growth for the company in the current year.

The company’s rapid progress in bringing YUTREPIA to market follows a recent legal victory. On May 30, 2025, the U.S. District Court for the Middle District of North Carolina ruled against United Therapeutics’ (NASDAQ: UTHR) request for a preliminary injunction and a temporary restraining order. United Therapeutics had sought to block the commercialization of YUTREPIA, alleging patent infringement. The court’s decision has cleared the way for Liquidia to proceed with the product’s launch. The market has responded positively to these developments, with Liquidia’s stock showing strong momentum, gaining nearly 33% over the past six months.

YUTREPIA, utilizing Liquidia’s proprietary PRINT® technology, is an inhaled dry-powder form of treprostinil, designed for enhanced lung deposition via oral inhalation. It has been studied in the INSPIRE trial for PAH patients and is currently under investigation in the ASCENT trial for those with PH-ILD.

Pulmonary arterial hypertension is a rare and progressive disease that affects an estimated 45,000 patients in the United States, while PH-ILD affects over 60,000. Both conditions can lead to right heart failure and death, and while there is no cure for PAH, treatments like YUTREPIA aim to alleviate symptoms and improve quality of life.

Liquidia’s CEO, Dr. Roger Jeffs, commented on the company’s expedited delivery of YUTREPIA to the market, emphasizing the desire to provide patients with immediate access to the new therapy. The company’s strategy includes positioning YUTREPIA as the prostacyclin treatment of choice for PAH and PH-ILD patients.

As the company moves forward with the commercialization of YUTREPIA, it continues to develop other therapies for rare cardiopulmonary diseases and holds a portfolio that includes a generic Treprostinil Injection for PAH.

This news is based on a press release statement from Liquidia Corporation.

In other recent news, Liquidia Technologies has seen several developments concerning its financial outlook and product advancements. The company recently received FDA approval for its product Yutrepia, intended for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. This approval has led to multiple analyst firms adjusting their price targets for Liquidia. H.C. Wainwright raised its target to $35, citing Yutrepia’s flexible dosing and potential market impact. Similarly, Scotiabank increased its target to $37, noting the product’s competitive pricing and comprehensive patient access programs. Raymond James also lifted its target to $33, emphasizing confidence in Yutrepia’s market entry potential. Meanwhile, Wells Fargo adjusted its target to $23, reflecting increased confidence in the company’s market positioning. BTIG maintained a Buy rating with a $37 target, highlighting reduced legal risks. These developments underscore Liquidia’s strategic moves and the analyst community’s positive outlook on its future market performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.